Improving treatment for brain and bone metastases in breast cancer
Targeting brain and bone metastases in metastatic breast cancer for improved patient survival
This study is looking for ways to help people with metastatic breast cancer by creating new treatments that can better reach and fight cancer in the brain and bones, which could lead to improved survival and slower disease progression.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11059072 on NIH RePORTER |
What this research studies
This research focuses on addressing the challenges of treating brain and bone metastases in patients with metastatic breast cancer. It aims to develop new drug analogs that can effectively penetrate the brain and overcome resistance to existing chemotherapy drugs. The study will involve optimizing a promising compound, SB-216, and creating novel drug conjugates that target bone metastases. Patients may benefit from innovative therapies that improve survival and reduce the progression of metastatic disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer who have brain or bone metastases.
Not a fit: Patients with early-stage breast cancer or those without metastases may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic breast cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in developing therapies targeting metastatic breast cancer, but this approach with SB-216 is novel and aims to address specific challenges in treatment.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Li, Wei — University of Tennessee Health Sci Ctr
- Study coordinator: Li, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.